


# 亞東創新發展股份有限公司

負責人：王健誠

網址：[https://www.ord.feg.com.tw/zh\\_TW](https://www.ord.feg.com.tw/zh_TW)

地址：106 臺北市大安區敦化南路 2 段 207 號 34 樓

電話：02-7727-2277



## 企業沿革

- 2005.07 於遠東紡織機材部成立生醫科技事業群
- 2006.12 生醫廠房建廠完成
- 2007.04 取得藥商許可執照（製造業／販賣業）
- 2007.05 取得首張 GMP 中、英證照以及 Class I 醫材許可證
- 2007.06 取得 ISO 13485：2003 證書
- 2008.01 改組為「亞東創新發展股份有限公司」
- 2009.04 取得「生物合成纖維膜」醫材許可證
- 2010.10 取得「人工骨替代物」醫材許可證
- 2013.05 共 15 項產品申請通過 CE 認證、共 30 項產品取得 TFDA 醫材許可證
- 2013.09 榮獲優良廠商協會國家品質金牌獎
- 2013.12 人工替代骨榮獲 SNQ 國家品質標章 銅獎
- 2014.05 Class I 敷料產品取得 US FDA Listing
- 2015.02 「人工骨替代物」取得 FDA 510(K)、取得「注射式人工骨替代物」醫材許可證
- 2016.07 取得「複合式牙科補骨泥」醫材許可證

- 2020.06 取得「舒膚貼醫療級口罩（未滅菌）」醫材許可證
- 2023.01 完成亞創新廠 QMS 稽核
- 2025.07 完成亞創新廠 QMS 續證稽核

## 主要產品

- ① 舒膚貼 傷口照護系列產品
- ② 舒派特 動物傷口照護系列產品
- ③ 尼諾斯 骨科材料系列產品
- ④ 奈斯飛 牙科補骨材料

## 企業簡介

亞東創新發展股份有限公司（Oriental Resources Development Limited）隸屬遠東集團，為集團底下首家跨足生醫科技領域的公司，成立於 2008 年，廠區位於新竹湖口，擁有通過 ISO 13485 認證的生產基地。

公司主力產品包括傷口照護系列「舒膚貼」、動物用傷口照護「舒派特」、骨科材料「尼諾斯」及牙科補骨材料「奈斯飛」，銷售遍及美洲與亞洲十餘國。

## 出口實績及國際競爭力

亞東創新發展股份有限公司隸屬遠東集團，由遠東新世紀全資持股，秉持集團「勤、誠、樸、慎、創新」的精神，2008 年自生醫科技事業群獨立以來，持續獲得集團在廠房、公用系統與營運上的全力支持。公司主要外銷產品深受國際大廠曼秀雷敦青睞，行銷東南亞各國，具品牌認證與市場競爭力；產品出口市場拓展至加拿大、美國、巴西等美洲國家。同時亦為國內上市公司代工人工皮與藻酸鈣敷料，並為馬來西亞客戶生產疤痕凝膠。巴西客戶除骨材產品外，現亦推進敷料認證，大陸市場的醫材認證亦同步進行中。遠東新世紀研發中心生醫組長期支援亞東創新，專注於新產品開發、技術升級與市場策略研擬，形成從研發、製造到銷售的整合優勢，持續為公司注入創新能量與永續發展動力。

## 營運管理與績效

企業以「創新改善全球生命品質」為使命，專注醫材與健康產業，推動低碳與數位轉型。研發團隊聚焦綠色產品與低碳製程，導入設計思考與產品生命週期評估（LCA），提升永續與市場競爭力。除了 ISO 13485 及 QMS 的認證之外，作業面採 ERP 系統，建立高效率、高品質的製造體系。



公司治理方面，設有獨立董事會與嚴謹的風險管控、稽核、內部控制等機制，並遵循母公司遠東新世紀的上市公司規範，確保經營透明與符合法規。財務管理上，採 KPI 及 ROE、ROA、EBITDA 等績效指標，以穩健策略支撐成長。人力資源政策重視員工健康、培訓與多元包容的企業文化，建立績效導向與彈性工時制度。


## 永續經營

亞東創新積極實踐 ESG 政策：

在環境面，設定 2050 年淨零排放目標，推行碳盤查、再生能源與循環包裝；在社會面，持續捐助陽光基金會等公益單位，並促進產學合作，善盡企業社會責任；在治理面，維持高度透明與倫理標準。其策略主軸為「創新驅動、綠色產品、永續供應鏈」，致力於將企業成功與社會責任融合，打造兼具效益與良心的生醫品牌。

## 綜合評語

1. 為國際大廠獨家代工，出口占比約 7 成，多位於亞洲國家，中國、馬來西亞及新加坡等市場。
2. 擁有 ISO 13485 及醫療器材品質管理系統準則認證，依客戶需求提供客製化產品設計。
3. 113 年進行碳盤查，與集團一起導入再生能源，採購綠電 115.4 度。






# ORIENTAL RESOURCES DEVELOPMENT LIMITED

Owner : David Wang

Website : <https://www.ord.feg.com.tw/>

Address : 1F., No. 30, Hefeng Rd., Hukou Township, Hsinchu County, Taiwan (R.O.C.), Zip code: 303

Tel : +886-3-5997135



## History

July 2005	Establishment of Biomedical Technology Business Group under the Textile Machinery Division of Far Eastern Textile Corporation.
December 2006	Construction completion of the biomedical factory.
April 2007	Obtained pharmaceutical manufacturer and distributor licenses.
May 2007	Acquired the first GMP (Good Manufacturing Practice) certificates in both Chinese and English, along with a Class I medical device license.
June 2007	Received ISO 13485:2003 certification.
January 2008	Reorganized as Oriental Resources Development Limited.
April 2009	Acquired medical device license for "Bio-synthetic Fiber Membrane."
October 2010	Acquired medical device license for "Artificial Bone Substitute."
May 2013	Achieved CE certification for 15 products and TFDA medical device licenses for 30 products.
September 2013	Awarded RCMA National Quality Gold Award.
December 2013	"Artificial Bone Substitute" received the SNQ - Bronze Award.
May 2014	Class I dressing products obtained

February 2015

US FDA Listing.  
"Artificial Bone Substitute" obtained US FDA 510(k), and "Injectable Bone Substitute" received a medical device license.

July 2016

Acquired medical device license for "Composite Dental Plaster."

June 2019

Received ISO 13485:2016 certification.

June 2020

Acquired medical device license for "ScarCare Medical Mask (Non-sterile)."

January 2023

Completed QMS (Quality Management System) audit for the new manufacturing plant.

## Business Items

- ① SavDerm - Wound Care Product Series
- ② SavPet - Veterinary Wound Care Product Series
- ③ NuROs - Orthopedic Material Series
- ④ NexFill - Dental Bone Grafting Material Series

## Introduction

Oriental Resources Development Limited (ORDL), a subsidiary of the Far Eastern Group, is its first company

in the group in the biomedical field. Established in 2008 with the factory in Hukou, Hsinchu, the company operates a QMS/ISO 13485-certified facility. Its major product lines include SavDerm (wound care), SavPet (veterinary care), NuROs (orthopedic materials), and NexFill (dental bone grafts), which are distributed across Taiwan, North and South America, and Southeast Asia.

## Export Competitiveness

Oriental Resources Development Limited (ORDL) is a wholly owned subsidiary of Far Eastern New Century (FENC), upholding the group's core values of sincerity, diligence, thrift, prudence, and innovation. Since the establishment in 2008, ORDL has received full support from the Far Eastern Group in terms of facilities, utilities, and business development. ORDL's major export products have earned recognition from the international brand Mentholatum, achieving high market competitiveness and credibility in Southeast Asia. Its export markets have expanded to North and South America, including Canada, the United States, and Brazil. The company also provides OEM services not only for domestic listed companies, producing artificial skin and calcium alginate dressings, but also for clients in Malaysia, manufacturing scar gels. In addition to bone graft sales, Brazilian partners have begun product certification for wound dressings. Certification for the Chinese market is also underway. The Biomedical Division of FENC's R&D Center has long supported ORDL in new product development, technological advancement, and strategic planning, forming an integrated value chain from R&D and manufacturing to sales—continuously driving innovation and sustainable growth.

## Operation Performance Management

With the mission of "Innovating to Improve Global Quality of Life," ORDL focuses on sustainable biomedical solutions. Its strategy centers on low-carbon transition, digital transformation, and smart manufacturing. The R&D division emphasizes eco-friendly materials and low-carbon manufacturing process by adapting green power and carbon footprint verification to minimize environmental impact and boost market competitiveness. ORDL has adopted an ERP system besides ISO 13485 and QMS, ensuring the efficiency and consistency of its manufacturing system.

In terms of corporate governance, ORDL has an independent board of directors and a rigorous risk

management mechanism, complying with the regulations of the public listed parent company, FENC. The company maintains strict financial discipline, internal control and auditing with KPI-driven management and performance indicators such as ROE, ROA, and EBITDA to support stable growth. The human resources policy emphasizes employee health, training, and a diverse and inclusive corporate culture, establishing a performance-oriented and flexible working hours policy.

## Sustainable Management

Under its ESG policy, ORDL commits to:

- ① Environmental: ORDL aims to achieve Net Zero by 2050, implementing carbon footprint verification, renewable energy, and sustainable packaging.
- ② Social: ORDL continuously supports welfare organizations such as Sunshine Foundation, etc., and fosters academic-industry collaboration for social responsibilities.
- ③ Governance: ORDL ensures transparency and ethical standards.
- ④ ORDL is committed to integrating corporate successes with social responsibility to create a biomedical brand that combines efficiency and conscience.

